Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06058650 · ClinicalTrials.gov registry record · NA

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

A NA study of Breast Neoplasm, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT06058650: Recruiting NA study of Breast Neoplasm, sponsored by Mayo Clinic.

NCT06058650 is a NA study of Breast Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 70 participants, below the 160-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06058650, a NA study of Breast Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken. Sometimes a lesion or part of the lesion cannot be seen on ultrasound or mammography, and, therefore, a biopsy guided with ultrasound or mammography may not be always be accurate. Studies have shown that high resolution MBI may have potential to improve the detection of some breast tumors. This trial uses a new high-resolution MBI system that may help perform a biopsy using MBI.

Primary Outcome

Time from injection of the technetium Tc-99m sestamibi to identification of the appropriate needle guide hole will be reviewed to determine if and where any improvements in workflow can be made to reduce the overall procedure time for patients.

Conditions Studied

Interventions

  • OTHER Medical Device Usage and Evaluation
  • PROCEDURE Biopsy of Breast
  • RADIATION Scintimammography
  • OTHER Technetium Tc-99m Sestamibi

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2021-08-26
Est. Completion 2026-08-26
Phase NA
Mayo Clinic

2,844 total trials

What NCT06058650 shows while recruiting

NCT06058650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 160-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (56% lower).

The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Medical Device Usage and Evaluation is the first listed.

NCT06058650 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06058650 about?

NCT06058650 is a clinical study titled "Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities". This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is take...

What is the current status of trial NCT06058650?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2021-08-26. Estimated completion is 2026-08-26.

What conditions does trial NCT06058650 study?

This clinical trial studies the following conditions: Breast Neoplasm.

What interventions are being tested in trial NCT06058650?

The interventions under investigation include: Medical Device Usage and Evaluation (OTHER), Biopsy of Breast (PROCEDURE), Scintimammography (RADIATION), Technetium Tc-99m Sestamibi (OTHER).

Who is sponsoring clinical trial NCT06058650?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06058650 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06058650's enrollment target sits among peer trials

70 16th of 26 higher than 11 of 26 other Breast Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06058650, the US trial registry maintained by the National Library of Medicine. NCT06058650 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.